Aurobindo Pharma Limited, has received approval from Health Canada — a department of the Canadian government with responsibility for national public health — for its abbreviated new drug submission Gabapentin capsules in 100mg, 300mg and 400mg strengths. This is Aurobindo’s sixth approval from Health Canada.
Gabapentin capsules 100mg, 300mg and 400mg is the generic equivalent of Pfizer Canada Inc’s Neurontin capsules 100mg, 300mg and 400mg, which falls under the central nervous system (CNS) segment indicated for the treatment of seizures in patients diagnosed with epilepsy, the company stated in a release on Tuesday.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app